Atrial natriuretic peptide in cardiovascular biology and disease (NPPA).

Atrial natriuretic peptide (ANP) is a cardiac hormone that regulates salt-water balance and blood pressure by promoting renal sodium and water excretion and stimulating vasodilation. ANP also has an anti-hypertrophic function in the heart, which is independent of its systemic blood pressure-lowering effect. In mice, ANP deficiency causes salt-sensitive hypertension and cardiac hypertrophy. Recent studies have shown that ANP plays an important role in regulating vascular remodeling and energy metabolism. Variants in the human NPPA gene, encoding the ANP precursor, are associated with hypertension, stroke, coronary artery disease, heart failure (HF) and obesity. ANP and related peptides are used as biomarkers for heart disease. Recombinant proteins and small molecules that enhance the ANP pathway have been developed to treat patients with HF. In this review, we discuss the role of ANP in cardiovascular biology and disease.

[1]  F. Theilig,et al.  ANP-induced signaling cascade and its implications in renal pathophysiology. , 2015, American journal of physiology. Renal physiology.

[2]  D. Levy,et al.  Association of Plasma Natriuretic Peptide Levels With Metabolic Risk Factors in Ambulatory Individuals , 2007, Circulation.

[3]  J. Qin,et al.  Corin Variant Associated With Hypertension and Cardiac Hypertrophy Exhibits Impaired Zymogen Activation and Natriuretic Peptide Processing Activity , 2008, Circulation research.

[4]  Xiping Xu,et al.  Association between human atrial natriuretic peptide Val7Met polymorphism and baseline blood pressure, plasma trough irbesartan concentrations, and the antihypertensive efficacy of irbesartan in rural Chinese patients with essential hypertension. , 2005, Clinical therapeutics.

[5]  J. Goetze,et al.  Atrial natriuretic peptides in plasma. , 2015, Clinica chimica acta; international journal of clinical chemistry.

[6]  Junliang Pan,et al.  Genomic Structures of the Human and Murine Corin Genes and Functional GATA Elements in Their Promoters* , 2002, The Journal of Biological Chemistry.

[7]  D. Durocher,et al.  Combinatorial interactions regulating cardiac transcription. , 1998, Developmental genetics.

[8]  D. Arnett,et al.  A review of the role of atrial natriuretic peptide gene polymorphisms in hypertension and its sequelae , 2009, Current hypertension reports.

[9]  M. Liu,et al.  Corin Mutation R539C from Hypertensive Patients Impairs Zymogen Activation and Generates an Inactive Alternative Ectodomain Fragment* , 2013, The Journal of Biological Chemistry.

[10]  H. Huikuri,et al.  Natriuretic Peptides and Mortality After Stroke , 2005, Stroke.

[11]  H. Itoh,et al.  Atrial Natriuretic Polypeptide as a Novel Antigrowth Factor of Endothelial Cells , 1992, Hypertension.

[12]  T. Wieland,et al.  The natriuretic peptide/guanylyl cyclase--a system functions as a stress-responsive regulator of angiogenesis in mice. , 2009, The Journal of clinical investigation.

[13]  J. Knowles,et al.  Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice. , 2001, The Journal of clinical investigation.

[14]  D. Levy,et al.  Impact of Obesity on Plasma Natriuretic Peptide Levels , 2004, Circulation.

[15]  S. Johansson,et al.  Atrial natriuretic peptide as a predictor of atrial fibrillation in a male population study. The Study of Men Born in 1913 and 1923. , 2014, International Journal of Cardiology.

[16]  D. Garbers,et al.  Salt-resistant hypertension in mice lacking the guanylyl cyclase-A receptor for atrial natriuretic peptide , 1995, Nature.

[17]  S. Chien,et al.  Cardiac developmental defects and eccentric right ventricular hypertrophy in cardiomyocyte focal adhesion kinase (FAK) conditional knockout mice , 2008, Proceedings of the National Academy of Sciences.

[18]  A. Kenny,et al.  Role of endopeptidase‐24.11 in the inactivation of atrial natriuretic peptide , 1988, FEBS letters.

[19]  A. Hafezi-Moghadam,et al.  Atrial natriuretic peptide reduces vascular leakage and choroidal neovascularization. , 2009, The American journal of pathology.

[20]  Y. Yazaki,et al.  Evaluation of the atrial natriuretic peptide gene in stroke. , 2002, Atherosclerosis.

[21]  M. de Andrade,et al.  Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation. , 2008, The New England journal of medicine.

[22]  Yoshihiko Saito.  Roles of atrial natriuretic peptide and its therapeutic use. , 2010, Journal of cardiology.

[23]  Tara M. Holmes,et al.  Atrial natriuretic peptide is negatively regulated by microRNA-425. , 2013, The Journal of clinical investigation.

[24]  P. Trindade,et al.  Mechanisms of natriuretic-peptide-induced growth inhibition of vascular smooth muscle cells. , 1997, Cardiovascular research.

[25]  H. Mitani,et al.  Four functionally distinct C-type natriuretic peptides found in fish reveal evolutionary history of the natriuretic peptide system , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[26]  Thomas J. Wang,et al.  Low plasma level of atrial natriuretic peptide predicts development of diabetes: the prospective Malmo Diet and Cancer study. , 2012, The Journal of clinical endocrinology and metabolism.

[27]  T. Shibasaki,et al.  GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure , 2013, Nature Medicine.

[28]  L. Zagato,et al.  Association of atrial natriuretic peptide and type a natriuretic peptide receptor gene polymorphisms with left ventricular mass in human essential hypertension. , 2006, Journal of the American College of Cardiology.

[29]  K. Nakao,et al.  Inhibition of TRPC6 Channel Activity Contributes to the Antihypertrophic Effects of Natriuretic Peptides-Guanylyl Cyclase-A Signaling in the Heart , 2010, Circulation research.

[30]  G. Ailhaud,et al.  Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. , 2012, The Journal of clinical investigation.

[31]  Chung-Jen Lee,et al.  Inverse association of long-acting natriuretic peptide with metabolic syndrome in congestive heart failure patients , 2013, Diabetology & Metabolic Syndrome.

[32]  Q. Wu,et al.  Role of corin and atrial natriuretic peptide in preeclampsia. , 2013, Placenta.

[33]  J. Huidobro-Toro,et al.  Molecular mechanism of cGMP‐mediated smooth muscle relaxation , 2000, Journal of cellular physiology.

[34]  Kenji Nakamura,et al.  Cardiac fibrosis in mice lacking brain natriuretic peptide. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[35]  K. Nicolaides,et al.  Longitudinal changes in maternal corin and mid‐regional proatrial natriuretic peptide in women at risk of pre‐eclampsia , 2015, Ultrasound in obstetrics & gynecology : the official journal of the International Society of Ultrasound in Obstetrics and Gynecology.

[36]  O. Smithies,et al.  Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension , 1995, Science.

[37]  Junliang Pan,et al.  Processing of Pro-atrial Natriuretic Peptide by Corin in Cardiac Myocytes* , 2002, The Journal of Biological Chemistry.

[38]  J. Morser,et al.  Functional Analysis of the Transmembrane Domain and Activation Cleavage of Human Corin , 2003, Journal of Biological Chemistry.

[39]  S. Pikkarainen,et al.  Key roles of endothelin-1 and p38 MAPK in the regulation of atrial stretch response. , 2011, American journal of physiology. Regulatory, integrative and comparative physiology.

[40]  M. Adams,et al.  Gestational hypertension in atrial natriuretic peptide knockout mice and the developmental origins of salt-sensitivity and cardiac hypertrophy , 2013, Regulatory Peptides.

[41]  W. Forssmann,et al.  Urodilatin: a newly described member of the ANP family. , 1989, Trends in pharmacological sciences.

[42]  Robert J Glynn,et al.  Natriuretic Peptide Precursor A Gene Polymorphisms and Risk of Blood Pressure Progression and Incident Hypertension , 2007, Hypertension.

[43]  M. Volpe,et al.  Atrial natriuretic peptide (ANP) gene promoter variant and increased susceptibility to early development of hypertension in humans , 2007, Journal of Human Hypertension.

[44]  L. Mandelbrot,et al.  Highly Significant Association between Two Common Single Nucleotide Polymorphisms in CORIN Gene and Preeclampsia in Caucasian Women , 2014, PloS one.

[45]  B. Gigante,et al.  Atrial Natriuretic Peptide Gene Polymorphisms and Risk of Ischemic Stroke in Humans , 2004, Stroke.

[46]  J. Qin,et al.  Corin Mutations K317E and S472G from Preeclamptic Patients Alert Zymogen Activation and Cell Surface Targeting* , 2014, The Journal of Biological Chemistry.

[47]  M. Kurabayashi,et al.  Effects of intravenous atrial natriuretic peptide on cardiac sympathetic nerve activity and left ventricular remodeling in patients with first anterior acute myocardial infarction. , 2007, Journal of the American College of Cardiology.

[48]  Y. Yazaki,et al.  Genetic analysis of the atrial natriuretic peptide gene in essential hypertension. , 2000, Clinical science.

[49]  P. Ponikowski,et al.  Ularitide for the treatment of acute decompensated heart failure: from preclinical to clinical studies , 2015, European heart journal.

[50]  K. Okumura,et al.  Renal protective effects and the prevention of contrast-induced nephropathy by atrial natriuretic peptide. , 2009, Journal of the American College of Cardiology.

[51]  F. Crampes,et al.  Atrial natriuretic peptide contributes to the physiological control of lipid mobilization in humans , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[52]  Daniel Levy,et al.  Plasma natriuretic peptide levels and the risk of cardiovascular events and death. , 2004, The New England journal of medicine.

[53]  J. Burnett,et al.  M-Atrial Natriuretic Peptide: A Novel Antihypertensive Protein Therapy , 2012, Current Hypertension Reports.

[54]  A. D. de Bold,et al.  A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats. , 1981, Life sciences.

[55]  K. Nakao,et al.  Calcineurin–Nuclear Factor of Activated T Cells Pathway–Dependent Cardiac Remodeling in Mice Deficient in Guanylyl Cyclase A, a Receptor for Atrial and Brain Natriuretic Peptides , 2005, Circulation.

[56]  W. Dole,et al.  Hypertension in mice lacking the proatrial natriuretic peptide convertase corin. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[57]  K. Bailey,et al.  The Atrial Natriuretic Peptide Genetic Variant rs5068 Is Associated With a Favorable Cardiometabolic Phenotype in a Mediterranean Population , 2013, Diabetes Care.

[58]  G. Sharma,et al.  Genetic disruption of atrial natriuretic peptide receptor-A alters renin and angiotensin II levels. , 2001, American journal of physiology. Renal physiology.

[59]  Y. O. Xu-Cai,et al.  Corin: new insights into the natriuretic peptide system. , 2009, Kidney international.

[60]  A. Hirayama,et al.  Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials , 2007, The Lancet.

[61]  M. Condorelli,et al.  Prediction of Long‐Term Survival in Chronic Heart Failure by Multiple Biomarker Assessment: A 15‐Year Prospective Follow‐Up Study , 2010, Clinical cardiology.

[62]  S. Palmer,et al.  First identification of circulating prepro-A-type natriuretic peptide (preproANP) signal peptide fragments in humans: initial assessment as cardiovascular biomarkers. , 2012, Clinical chemistry.

[63]  D. Dickey,et al.  Natriuretic peptides, their receptors, and cyclic guanosine monophosphate-dependent signaling functions. , 2006, Endocrine reviews.

[64]  P. Ridker,et al.  The gene encoding atrial natriuretic peptide and the risk of human stroke. , 1999, Circulation.

[65]  Varsha Bhakta,et al.  Characterization of a long-acting recombinant human serum albumin-atrial natriuretic factor (ANF) expressed in Pichia pastoris , 2012, Regulatory Peptides.

[66]  M. Zeidel.  Renal actions of atrial natriuretic peptide: regulation of collecting duct sodium and water transport. , 1990, Annual review of physiology.

[67]  J. Burnett,et al.  Designer natriuretic peptides: a vision for the future of heart failure therapeutics. , 2011, Canadian journal of physiology and pharmacology.

[68]  Chung-Jen Lee,et al.  Low serum long-acting natriuretic peptide level correlates with metabolic syndrome in hypertensive patients: a cross-sectional study. , 2013, Archives of medical research.

[69]  A. Jaffe,et al.  Cross-reactivity of BNP, NT-proBNP, and proBNP in commercial BNP and NT-proBNP assays: preliminary observations from the IFCC Committee for Standardization of Markers of Cardiac Damage. , 2008, Clinical chemistry.

[70]  J. Laragh,et al.  Effects of auriculin (atrial natriuretic factor) on blood pressure, renal function, and the renin-aldosterone system in dogs. , 1984, The American journal of medicine.

[71]  M. Yanagisawa,et al.  Vascular endothelium is critically involved in the hypotensive and hypovolemic actions of atrial natriuretic peptide. , 2005, The Journal of clinical investigation.

[72]  J. Jordan,et al.  Natriuretic peptides enhance the oxidative capacity of human skeletal muscle. , 2012, Journal of Clinical Investigation.

[73]  W. Forssmann,et al.  The renal urodilatin system: clinical implications. , 2001, Cardiovascular research.

[74]  D. Levy,et al.  Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure , 2009, Nature Genetics.

[75]  G. Dedoussis,et al.  Natriuretic peptide Val7Met substitution and risk of coronary artery disease in Greek patients with familial hypercholesterolemia , 2006, Journal of clinical laboratory analysis.

[76]  Stephen M Schwartz,et al.  Vascular Remodeling: Hemodynamic and Biochemical Mechanisms Underlying Glagov’s Phenomenon , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[77]  Akshay S. Desai,et al.  Angiotensin-neprilysin inhibition versus enalapril in heart failure. , 2014, The New England journal of medicine.

[78]  M. Kuhn.  Cardiac actions of atrial natriuretic peptide: new visions of an old friend. , 2015, Circulation research.

[79]  M. Volpe,et al.  NT-proANP circulating level is a prognostic marker in stable ischemic heart disease. , 2012, International journal of cardiology.

[80]  E. Boerwinkle,et al.  Pharmacogenetic association of the NPPA T2238C genetic variant with cardiovascular disease outcomes in patients with hypertension. , 2008, JAMA.

[81]  R. Zimmerman,et al.  Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. , 1988, Circulation research.

[82]  M. Drazner,et al.  Corin Gene Minor Allele Defined by 2 Missense Mutations Is Common in Blacks and Associated With High Blood Pressure and Hypertension , 2005, Circulation.

[83]  T. Kudo,et al.  Inhibition of aldosterone production in the adrenal glomerulosa by atrial natriuretic factor , 1984, Nature.

[84]  R. Busse,et al.  Involvement of a cGMP-dependent Pathway in the Natriuretic Peptide-mediated Hormone-sensitive Lipase Phosphorylation in Human Adipocytes* , 2003, Journal of Biological Chemistry.

[85]  J. Morser,et al.  Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[86]  P. Ridker,et al.  Association of 77 polymorphisms in 52 candidate genes with blood pressure progression and incident hypertension: the Women's Genome Health Study , 2008, Journal of hypertension.

[87]  M. Berlan,et al.  Natriuretic peptides: a new lipolytic pathway in human adipocytes , 2000, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[88]  R. Pijnenborg,et al.  The uterine spiral arteries in human pregnancy: facts and controversies. , 2006, Placenta.

[89]  W. Forssmann,et al.  Urodilatin (CDD/ANP‐95‐126) is not biologically inactivated by a peptidase from dog kidney cortex membranes in contrast to atrial natriuretic peptide/cardiodilatin (α‐hANP/CDD‐99‐126) , 1988, FEBS letters.

[90]  Michael D. Schneider,et al.  Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A. , 2003, The Journal of clinical investigation.

[91]  K. Bailey,et al.  Atrial Natriuretic Peptide Genetic Variant rs5065 and Risk for Cardiovascular Disease in the General Community: A 9-Year Follow-Up Study , 2013, Hypertension.

[92]  Aili Wang,et al.  A Corin Variant Identified in Hypertensive Patients That Alters Cytoplasmic Tail and Reduces Cell Surface Expression and Activity , 2014, Scientific Reports.

[93]  W. Niu.  The Relationship between Natriuretic Peptide Precursor a Gene T2238C Polymorphism and Hypertension: A Meta-Analysis , 2011, International journal of hypertension.

[94]  S. Miyano,et al.  Contribution of comparative fish studies to general endocrinology: structure and function of some osmoregulatory hormones. , 2006, Journal of experimental zoology. Part A, Comparative experimental biology.

[95]  Jingjing Jiang,et al.  Salt-Sensitive Hypertension and Cardiac Hypertrophy in Transgenic Mice Expressing a Corin Variant Identified in Blacks , 2012, HYPERTENSION.

[96]  Jeffrey Robbins,et al.  A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy , 1998, Cell.

[97]  O. Pongs,et al.  A cardiac pathway of cyclic GMP-independent signaling of guanylyl cyclase A, the receptor for atrial natriuretic peptide , 2011, Proceedings of the National Academy of Sciences.

[98]  A. D. de Bold,et al.  The heart as an endocrine organ , 2014, Endocrine connections.

[99]  M. Tomita,et al.  Cardiovascular and renal effects of carperitide and nesiritide in cardiovascular surgery patients: a systematic review and meta-analysis , 2011, Critical care.

[100]  F. Van de Werf,et al.  Influence of rs5065 atrial natriuretic peptide gene variant on coronary artery disease. , 2012, Journal of the American College of Cardiology.

[101]  T. Flynn,et al.  Salt-sensitive hypertension in ANP knockout mice: potential role of abnormal plasma renin activity. , 1998, American journal of physiology. Regulatory, integrative and comparative physiology.

[102]  D. Goeddel,et al.  Molecular Biology of the Natriuretic Peptides and Their Receptors , 1992, Circulation.

[103]  M. Volpe,et al.  C2238 Atrial Natriuretic Peptide Molecular Variant Is Associated With Endothelial Damage and Dysfunction Through Natriuretic Peptide Receptor C Signaling , 2013, Circulation research.

[104]  J. Burnett,et al.  A human atrial natriuretic peptide gene mutation reveals a novel peptide with enhanced blood pressure-lowering, renal-enhancing, and aldosterone-suppressing actions. , 2009, Journal of the American College of Cardiology.

[105]  W. Cheng,et al.  Role of corin in trophoblast invasion and uterine spiral artery remodelling in pregnancy , 2012, Nature.

[106]  Y. O. Xu-Cai,et al.  Molecular forms of natriuretic peptides in heart failure and their implications , 2009, Heart.

[107]  S. Lehnart,et al.  Microdomain switch of cGMP-regulated phosphodiesterases leads to ANP-induced augmentation of β-adrenoceptor-stimulated contractility in early cardiac hypertrophy. , 2015, Circulation research.

[108]  M. Volpe,et al.  The C2238/αANP Variant Is a Negative Modulator of Both Viability and Function of Coronary Artery Smooth Muscle Cells , 2014, PloS one.

[109]  J. Qin,et al.  Corin mutations K317E and S472G from preeclamptic patients alter zymogen activation and cell surface targeting. , 2014, The Journal of Biological Chemistry.

[110]  S. Solomon,et al.  Evaluation of Multiple Biomarkers of Cardiovascular Stress for Risk Prediction and Guiding Medical Therapy in Patients With Stable Coronary Disease , 2012, Circulation.

[111]  J. Morser,et al.  Corin, a Mosaic Transmembrane Serine Protease Encoded by a Novel cDNA from Human Heart* , 1999, The Journal of Biological Chemistry.

[112]  J. Burnett,et al.  A gut-heart connection in cardiometabolic regulation , 2013, Nature Medicine.

[113]  Jingjing Jiang,et al.  Impaired sodium excretion and salt-sensitive hypertension in corin-deficient mice , 2012, Kidney international.

[114]  K. Bailey,et al.  A genetic variant of the atrial natriuretic peptide gene is associated with cardiometabolic protection in the general community. , 2011, Journal of the American College of Cardiology.

[115]  H. Itoh,et al.  Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth muscle cells. , 1990, The Journal of clinical investigation.

[116]  O. Pongs,et al.  Novel insights into the mechanisms mediating the local antihypertrophic effects of cardiac atrial natriuretic peptide: role of cGMP-dependent protein kinase and RGS2 , 2010, Basic Research in Cardiology.

[117]  J. Knowles,et al.  Evidence for a novel natriuretic peptide receptor that prefers brain natriuretic peptide over atrial natriuretic peptide. , 2001, The Biochemical journal.

[118]  D. Dickey,et al.  A Familial Mutation Renders Atrial Natriuretic Peptide Resistant to Proteolytic Degradation* , 2009, The Journal of Biological Chemistry.

[119]  F. Crampes,et al.  Control of lipolysis by natriuretic peptides and cyclic GMP , 2008, Trends in Endocrinology & Metabolism.

[120]  M. Volpe,et al.  Atrial natriuretic peptide gene variants and circulating levels: implications in cardiovascular diseases. , 2014, Clinical science.

[121]  S. Oparil,et al.  Pressure‐independent enhancement of cardiac hypertrophy in atrial natriuretic peptide–deficient mice , 2003, Clinical and experimental pharmacology & physiology.

[122]  K. Nakao,et al.  Impaired Recovery of Blood Flow After Hind-Limb Ischemia in Mice Lacking Guanylyl Cyclase-A, a Receptor for Atrial and Brain Natriuretic Peptides , 2009, Arteriosclerosis, thrombosis, and vascular biology.

[123]  K. Nakao,et al.  Natriuretic Peptides/cGMP/cGMP-Dependent Protein Kinase Cascades Promote Muscle Mitochondrial Biogenesis and Prevent Obesity , 2009, Diabetes.

[124]  A. Hirayama,et al.  Continuous low-dose infusion of human atrial natriuretic peptide in patients with left ventricular dysfunction undergoing coronary artery bypass grafting: the NU-HIT (Nihon University working group study of low-dose Human ANP Infusion Therapy during cardiac surgery) for left ventricular dysfunction. , 2010, Journal of the American College of Cardiology.

[125]  A. D. Bold,et al.  Atrial natriuretic factor: a hormone produced by the heart. , 1985, Science.

[126]  D. Garbers,et al.  A genetic model provides evidence that the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte hypertrophy , 2001, Proceedings of the National Academy of Sciences of the United States of America.